Schedule III Marijuana Would Still Be Regulated Marijuana
FDA Law Blog: Biosimilars
MARCH 24, 2025
In January a public hearing began to receive factual evidence and testimony on whether marijuana should be rescheduled. Dispensing marijuana to patients, as required for other schedule III substances, would require a prescription issued for legitimate medical purpose by a DEA-registered and state licensed practitioner.
Let's personalize your content